Further evidence for genetic variation at the serotonin transporter gene SLC6A4 contributing toward anxiety

Forstner, Andreas J.; Rambau, Stefanie; Friedrich, Nina; Ludwig, Kerstin U.; Böhmer, Anne C.; Mangold, Elisabeth; Maaser, Anna; Hess, Timo; Kleiman, Alexandra; Bittner, Antje; Nöthen, Markus M.; Becker, Jéssica; Geiser, Franziska; Schumacher, Johannes; Conrad, Rupert

doi:10.1097/ypg.0000000000000171

Cited by 31 publications

(25 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is consistent with the previous study reported that only SNP rs140701 was associated with PD in a 163 sample of African American [9]. Similar studies have found a nominally significant association of rs140701 with social anxiety disorder [38]. The 5-HTT is encoded by the solute carrier family 6 member 4 (SLC6A4) gene, at locus 17q11.2.…”

Section: Discussionsupporting

confidence: 92%

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

et al. 2020

View full text Add to dashboard Cite

Background: A number of studies have shown that genetic factor plays an important role in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug. Methods: Two hundred thirty-three patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association. Results: The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR = 0.624, 95% CI 0.450-0.864, p < 0.05), and a significant result was found in the dominant model (OR = 0.546; 95% CI, 0.371-0.804, p < 0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95% CI 0.128-0.328; OR = 0.249, 95% CI 0.155-0.401, both p < 0.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers. Conclusions: The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.

show abstract

Section: Discussionsupporting

confidence: 92%

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This result is consistent with the previous study reported that only SNP rs140701 was associated with PD in a 163 sample of African American [9]. Similar studies have found a nominally signi cant association of rs140701 with social anxiety disorder [38]. The 5-HTT is encoded by the solute carrier family 6 member 4 (SLC6A4) gene, at locus 17q11.2.…”

Section: Discussionsupporting

confidence: 92%

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

Zou

Huang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: A number of studies have shown that genetic factor plays an important role in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug. Methods: 233 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association. Results: The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR = 0.624, 95 % CI 0.450-0.864, p <0.05), and a significant result was found in the dominant model (OR = 0.546; 95% CI, 0.371-0.804, p <0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95 % CI 0.128-0.328; OR = 0.249, 95 % CI 0.155-0.401, both p <0.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers. Conclusion s : The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.

show abstract

“…This result is consistent with the previous study reported that only SNP rs140701 was associated with PD in a 163 sample of African American [9]. Similar studies have found a nominally signi cant association of rs140701 with social anxiety disorder [38]. The serotonin transporter (5-HTT) is encoded by the solute carrier family 6 (neurotransmitter transporter) member 4 (SLC6A4) gene, at locus 17q11.2.…”

Section: Discussionsupporting

confidence: 92%

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

Zou

Huang

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: A number of studies have shown that genetic factor plays an importantrole in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug.Methods: 233 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association.Results: The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR = 0.624, 95 % CI 0.450-0.864, p<0.05), and a significant result was found in the dominant model (OR = 0.546; 95% CI, 0.371-0.804, p<0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95 % CI 0.128-0.328; OR = 0.249, 95 % CI 0.155-0.401, both p <0.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers.Conclusions: The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.

show abstract

Further evidence for genetic variation at the serotonin transporter gene SLC6A4 contributing toward anxiety

Cited by 31 publications

References 58 publications

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

Contact Info

Product

Resources

About